16:14 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Infectious Cell culture and mouse studies identified a boronpleuromutilin-based compound that could help treat lymphatic filariasis and onchocerciasis, which are caused by Brugia malayi , Litomosoides sigmodontis and other filarial nematodes and dependent on...
21:10 , Oct 3, 2017 |  BC Extra  |  Company News

Management tracks: CRISPR Therapeutics, Momenta

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) promoted Samarth Kulkarni to CEO from president of the company's U.S. subsidiary CRISPR Therapeutics Inc., effective Dec. 1. He will succeed Rodger Novak, who will serve as president...
22:02 , Apr 12, 2017 |  BC Extra  |  Company News

Management tracks

Bioprinting company Organovo Holdings Inc. (NASDAQ:ONVO) said CEO Keith Murphy will resign, effective April 21. Taylor Crouch, who was CEO of eStudySite (San Diego, Calif.), will succeed him. Kidney disease company Tricida Inc. (South San...
00:38 , Apr 1, 2017 |  BC Extra  |  Company News

Management tracks

Immuno-oncology company Forty Seven Inc. (Palo Alto, Calif.) named Mark McCamish CEO, effective May 1. He was global head of biopharmaceutical development at the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN). Founding CEO Jonathan MacQuitty...
23:19 , Dec 15, 2016 |  BC Week In Review  |  Clinical News

Eucrisa regulatory update

FDA approved an NDA from Pfizer for Eucrisa crisaborole 2% ointment to treat mild to moderate atopic dermatitis in patients ages ≥2. Pfizer said the company plans to launch Eucrisa by the end of January...
01:36 , Dec 15, 2016 |  BC Extra  |  Company News

FDA approves Pfizer eczema drug Eucrisa

FDA approved Eucrisa crisaborole (formerly AN2728 ) from Pfizer Inc. (NYSE:PFE) to treat mild to moderate atopic dermatitis in patients aged two and older. Pfizer spokesperson Steven Danehy said the company plans to launch Eucrisa...
00:02 , Dec 14, 2016 |  BC Extra  |  Company News

Management tracks

Gene editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) hired Graeme Bell as CFO, replacing Sapna Srivastava. Bell was CFO at Anacor Pharmaceuticals Inc. , which Pfizer Inc. (NYSE:PFE) acquired. Srivastava will remain as a senior advisor....
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

Anacor, Pfizer deal

Pfizer will acquire Anacor for $99.25 per share in cash, or about $5.2 billion net of cash. The price is a 55% premium to Anacor’s close of $64.03 on May 13, before the deal was...
01:11 , May 17, 2016 |  BC Extra  |  Top Story

Pfizer acquiring Anacor for $5.2B

Pfizer Inc. (NYSE:PFE) will acquire Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), giving it atopic dermatitis candidate crisaborole ( AN2728 ). The pharma will pay $99.25 per share in cash, or about $5.2 billion. The price is a...
07:00 , Apr 25, 2016 |  BioCentury  |  Politics, Policy & Law

SCOTUS to the rescue?

The U.S. Supreme Court will hear arguments on Monday in a case that could either overturn or reinforce policies that unfairly tilt the inter partes review system against patent holders, according to life sciences companies....